The UK and US have announced a landmark commercial pact that will maintain zero duties on British drug products entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the public health system. This move secures that duties on these crucial products will stay at zero for a period of 36 months.
This deal comes after recent threats to dramatically increase duties on patented drug products, with potential rates mentioned reaching double the cost.
"This arrangement between the UK strengthens the worldwide climate for innovative medicines and establishes much-needed fairness to transatlantic pharmaceutical trade," a release declared.
Trade Impact
Medicines constitute one of the the United Kingdom's most significant export categories to the United States, which is by far the largest market for major British pharmaceutical firms.
Statistics indicate that in the year prior to last September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This agreement protects jobs, boosts investment and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Key NHS Changes
The pact entails several key pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Last year, rebates topped twenty percent.
Industry Background
The pact follows a ongoing tension between the sector and the UK government over medicine costs and approval rates.
This friction were heightened by claims that American patients were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or scrapped, while major investments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
